Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Biochem ; 265(3): 1075-84, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10518804

ABSTRACT

To understand the effects of the immunosuppressant cyclosporin A (CsA) on Ca2+-mediated intracellular signalling pathways in human peripheral blood mononuclear cells (PBMCs), we investigated its effects on the activity profiles of mitogen-activated protein kinase (MAPK) cascades. PBMCs, or subpopulations thereof, were simultaneously stimulated with a phorbol ester and the calcium ionophore ionomycin, in the presence or absence of therapeutic concentrations of CsA. In these primary human cells, CsA significantly inhibited PMA/ionomycin-mediated and ionomycin-mediated activation of the MAPK kinase MKK6, as well as its downstream kinases SAPK2a (p38alpha) and MAPKAP-K2. PMA/ionomycin treatment also mediated activation of SAPK1 (JNKs) which was inhibited by CsA. Treatment with ionomycin alone also resulted in CsA-sensitive activation of SAPK1. With regard to transcription factors targeted by the Ca2+-induced MAPK signalling network, we found CsA to inhibit the ionomycin-mediated phosphorylation of ATF2 at Thr71. We identified the heterodimeric transcription factor ATF2/CREB as constitutively binding to the essential cAMP response element (CRE) site within the Ca2+-regulated DNA polymerase beta promoter and contributing to the activation of this promoter. Our data implicate ATF2 phosphorylation status as a nuclear sensor within PBMCs that monitors converging intracellular Ca2+-signalling pathways.


Subject(s)
Calcium Signaling/drug effects , Calcium-Calmodulin-Dependent Protein Kinases , Cyclosporine/pharmacology , Immunosuppressive Agents/pharmacology , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/metabolism , Mitogen-Activated Protein Kinases/metabolism , Activating Transcription Factor 2 , Base Sequence , Binding Sites , Calcineurin/metabolism , Cyclic AMP Response Element-Binding Protein/metabolism , DNA/genetics , Enzyme Activation/drug effects , Genes, pol/drug effects , Humans , In Vitro Techniques , Intracellular Signaling Peptides and Proteins , Ionomycin/pharmacology , JNK Mitogen-Activated Protein Kinases , Leukocytes, Mononuclear/enzymology , MAP Kinase Kinase 6 , Mitogen-Activated Protein Kinase Kinases/metabolism , Phosphorylation , Promoter Regions, Genetic , Protein Serine-Threonine Kinases/metabolism , Transcription Factors/metabolism , p38 Mitogen-Activated Protein Kinases
2.
Eur J Biochem ; 264(3): 952-9, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10491144

ABSTRACT

Alterations in gene expression may represent an underlying cause of undesired side-effects mediated by the immunosuppressant cyclosporin A (CsA). We employed the method of differential display PCR to identify new genes whose expression is modulated by CsA. Human peripheral blood mononuclear cells (PBMCs), or subpopulations thereof, were simultaneously stimulated with the phorbol ester 4beta-phorbol 12-myristate 13-acetate (PMA) and the calcium ionophore ionomycin, in the presence or absence of therapeutic concentrations of CsA. We identify the gene encoding the DNA repair enzyme DNA polymerase beta (Pol beta) as a novel CsA-sensitive transcription unit. Our data show that transcription of pol beta mRNA is induced by Ca2+ and that CsA significantly inhibits PMA/ionomycin- and ionomycin-mediated upregulation of both pol beta mRNA and Pol beta protein. The CsA-mediated inhibition of pol beta upregulation is maintained for at least 21 h after gene activation and is exerted via the phosphatase calcineurin. FK506, another immunosuppressant that targets calcineurin, also inhibits pol beta upregulation, while rapamycin competes with FK506 action. This work identifies Ca2+ as an inducer of pol beta gene activity in primary blood cells. The demonstrated CsA sensitivity of this process suggests a novel molecular mechanism that may contribute to the increased tumor incidence in patients receiving CsA treatment.


Subject(s)
Calcium/metabolism , Cyclosporine/adverse effects , DNA Polymerase beta/genetics , DNA Repair/drug effects , Immunosuppressive Agents/adverse effects , Animals , Base Sequence , Calcineurin/metabolism , DNA Polymerase beta/metabolism , DNA Primers/genetics , Humans , In Vitro Techniques , Ionomycin/pharmacology , Ionophores/pharmacology , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/metabolism , Neoplasms/etiology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Tacrolimus/pharmacology , Tetradecanoylphorbol Acetate/pharmacology , Up-Regulation/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...